FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]

연구 용도로만 사용. 전체 공지 →

스택 라이브러리

Retatrutide Stack

Fat Lossadvanced

87

상호작용

87
Share
펩타이드

2

일 평균 mcg

3,714

수준

advanced

추가됨

May 17, 2026

개요

The Retatrutide Stack is the most aggressive fat loss protocol in the peptide community, combining the triple-agonist GLP-1/GIP/glucagon receptor action of Retatrutide with Tesamorelin''s specific visceral fat reduction and GH-axis support. Retatrutide is a next-generation incretin-based peptide that activates three distinct metabolic receptors simultaneously: GLP-1 (appetite suppression and glucose regulation), GIP (enhanced fat metabolism and insulin sensitivity), and glucagon (direct fat mobilization and energy expenditure increase). Phase 2 clinical trials showed Retatrutide produced up to 24% total body weight reduction — the most powerful weight loss signal observed in any pharmaceutical compound to date. It remains investigational (not FDA-approved) at time of writing. Tesamorelin is the only FDA-approved growth hormone secretagogue, originally approved for HIV-related lipodystrophy (excess visceral fat). It is a GHRH analog that specifically targets visceral adipose tissue — the metabolically dangerous abdominal fat. By stimulating GH release, Tesamorelin drives lipolysis specifically in visceral fat depots while preserving lean muscle mass. This makes it an ideal complement to Retatrutide''s systemic fat mobilization. The combination targets fat loss through three independent mechanisms: appetite and glucose regulation (Retatrutide''s GLP-1 action), enhanced fat metabolism (Retatrutide''s GIP action), direct energy expenditure increase (Retatrutide''s glucagon action), and GH-driven visceral lipolysis (Tesamorelin). Together, the stack addresses both the appetite and metabolic sides of obesity while specifically targeting visceral fat — the most dangerous and most resistant-to-diet depot. Requires close medical supervision due to the potency of both compounds.

용량 프로토콜

Retatrutide

Once per week· subcutaneous

Retatrutide에 대한 자세한 내용 →

12,000 mcg

1회 용량당

Tesamorelin

Every day· subcutaneous

Tesamorelin에 대한 자세한 내용 →

2,000 mcg

1회 용량당

목표 및 증거

Aggressive fat lossVisceral fat reductionMetabolic optimizationBody recomposition
증거 등급:인체 데이터

경고

  • Retatrutide is investigational — not FDA-approved. GI side effects can be severe during dose escalation. Medical supervision required. Not appropriate for patients with pancreatitis history or thyroid C-cell tumors.

Comments

Sign in to join the discussion

주의: 이 스택은 커뮤니티에서 제출된 것이며 연구용으로만 사용됩니다. Peptide Contacts는 제출된 스택의 안전성이나 효능을 검증하지 않습니다. 펩타이드 프로토콜을 사용하기 전에 항상 자격이 있는 의료 전문가와 상의하세요.